Metabolomics seems to be helpful in elucidating the role of glycosylation in CDG caused by the c.320A>G ALG13 variant, in understanding the complex pathophysiology underlying a glycosylation deficiency, and in establishing new therapeutic approaches. The gene discussed is ALG13; the disease is congenital disorder of glycosylation.